The ADJUVANT/CTONG 1104 was a randomized controlled phase III study that compared adjuvant gefitinib with adjuvant chemotherapy in stage II–IIIA NSCLC patients who had the EGFR exon 19 deletion or exon 21 L858R mutation [69]. Here, EGFR is linked to non-small cell lung carcinoma.